Chacko Joseph A, Strati Paolo, Stout Paul W, Archer Robert L, Baltz Brad P, Chacko Joseph G
College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mult Scler Relat Disord. 2021 Apr;49:102776. doi: 10.1016/j.msard.2021.102776. Epub 2021 Jan 19.
There are multiple case reports in the literature describing an association between fingolimod and cutaneous neoplasms.
Investigate and report a case of a primary mediastinal large B-cell lymphoma in a patient on fingolimod for Relapsing-Remitting Multiple Sclerosis (RRMS).
Case Report.
The patient developed a primary mediastinal large B-cell lymphoma after seven years of treatment with fingolimod. The patient is currently in complete remission after cessation of treatment, surgical resection, chemotherapy, and radiation therapy.
This case report highlights the first primary mediastinal large B-cell lymphoma associated with fingolimod treatment. It should be considered a rare, but potential adverse effect of fingolimod.
文献中有多篇病例报告描述了芬戈莫德与皮肤肿瘤之间的关联。
调查并报告一例正在使用芬戈莫德治疗复发缓解型多发性硬化症（RRMS）的患者发生原发性纵隔大B细胞淋巴瘤的病例。
病例报告。
该患者在使用芬戈莫德治疗七年后发生原发性纵隔大B细胞淋巴瘤。目前，患者在停止治疗、手术切除、化疗和放疗后已完全缓解。
本病例报告突出了首例与芬戈莫德治疗相关的原发性纵隔大B细胞淋巴瘤。应将其视为芬戈莫德一种罕见但潜在的不良反应。
